Enhanced antitumor responses were also observed in parental CAL-27 and HN30 xenograft-bearing mice treated with cisplatin combined with STAT3-IN-1 (with tumor inhibition rates of 84.58%–90.38%) or CQ (with tumor inhibition rates of 80.62%–86.25%). This evidence concerns the gene STAT3 and neoplasm.